基于多序列MRI容积直方图分析预测局部晚期头颈部鳞状细胞癌新辅助化疗免疫治疗后病理完全缓解
本研究基于前瞻性II期试验的24例局部晚期头颈部鳞状细胞癌患者,提取新辅助化疗免疫治疗前后多序列MRI全肿瘤直方图特征构建预测模型。11例达病理完全缓解,联合模型预测性能最佳(AUC 0.95),优于AJCC分期(AUC 0.52)和RECIST 1.1(AUC 0.72)。
要点
- 联合模型预测病理完全缓解AUC 0.95,优于AJCC分期(AUC 0.52)和RECIST 1.1(AUC 0.72)。
- 治疗前T2WI直方图最小值、治疗后ADC平均绝对偏差、T1Gd偏度变化与病理完全缓解相关。
- 多序列MRI容积直方图分析可无创预测新辅助化疗免疫治疗后病理完全缓解状态。
核心结论
- 基于多序列MRI的容积直方图分析可无创预测接受新辅助化疗免疫治疗的局部晚期头颈部鳞状细胞癌患者的病理完全缓解状态,治疗前后提取的直方图特征显示出有前景的预测性能,为评估病理完全缓解提供了新的定量方法。
研究设计与样本
- 前瞻性II期试验中纳入24例局部晚期头颈部鳞状细胞癌患者进行分析,所有患者接受新辅助化疗免疫治疗前后MRI检查,提取T1WI、T2WI、增强T1WI(T1Gd)、扩散加权成像(DWI)序列及对应表观扩散系数(ADC)图的全肿瘤直方图特征,以病理结果分为病理完全缓解组和非病理完全缓解组,计算治疗前后直方图特征百分比变化(Delta特征),经数据降维和特征选择后用逻辑回归构建预测模型,用ROC分析评估诊断性能。
诊断标准与关键数值
- 24例中11例(11/24)达到病理完全缓解;与病理完全缓解相关的特征为治疗前T2WI原始一阶直方图最小值(Pre_T2_original_firstorder_Minimum)、治疗后ADC原始一阶直方图平均绝对偏差(Post_ADC_original_firstorder_MeanAbsoluteDeviation)和治疗前后T1Gd原始一阶直方图偏度变化(Delta_T1Gd_original_firstorder_Skewness);联合模型预测病理完全缓解的AUC为0.95,优于AJCC分期的AUC 0.52和RECIST 1.1的AUC 0.72;治疗前模型AUC 0.83,治疗后模型AUC 0.83,均优于AJCC分期。
临床应用与阅片要点
- 对于接受新辅助化疗免疫治疗的局部晚期头颈部鳞状细胞癌患者,可基于治疗前后多序列MRI提取全肿瘤容积直方图特征(包括T1WI、T2WI、T1Gd、DWI及ADC图)构建联合模型预测病理完全缓解,其预测性能优于常规AJCC分期和RECIST 1.1标准;原文结论认为该定量方法可为评估病理完全缓解提供新手段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to develop a multisequence MRI-based volumetric histogram metrics model for predicting pathological complete response (pCR) in advanced head and neck squamous cell carcinoma (HNSCC) patients undergoing neoadjuvant chemo-immunotherapy (NCIT) and compare its predictive performance with AJCC staging and RECIST 1.1 criteria.
METHODS: Twenty-four patients with locally advanced HNSCC from a prospective phase II trial were enrolled for analysis. All patients underwent pre- and post-NCIT MRI examinations from which whole-tumor histogram features were extracted, including T1WI, T2WI, enhanced T1WI (T1Gd), diffusion-weighted imaging (DWI) sequences, and their corresponding apparent diffusion coefficient (ADC) maps. The pathological results divided the patients into pathological complete response (pCR) and non-pCR (N-pCR) groups. Delta features were calculated as the percentage change in histogram features from pre- to post-treatment. After data reduction and feature selection, logistic regression was used to build prediction models. ROC analysis was performed to assess the diagnostic performance.
RESULTS: Eleven of 24 patients achieved pCR. Pre_T2_original_firstorder_Minimum, Post_ADC_original_firstorder_MeanAbsoluteDeviation, and Delta_T1Gd_original_firstorder_Skewness were associated with achieving pCR after NCIT. The Combined_Model demonstrated the best predictive performance (AUC 0.95), outperforming AJCC staging (AUC 0.52) and RECIST 1.1 (AUC 0.72). The Pre_Model (AUC 0.83) or Post-Model (AUC 0.83) had a better predictive ability than AJCC staging.
CONCLUSION: Multisequence MRI-based volumetric histogram analysis can non-invasively predict the pCR status of HNSCC patients undergoing NCIT. The use of histogram features extracted from pre- and post-treatment MRI exhibits promising predictive performance and offers a novel quantitative assessment method for evaluating pCR in HNSCC patients receiving NCIT.
引用
- Liu H, Zhu C, Wang X, et al. Prediction of pathological complete response in locally advanced head and neck squamous cell carcinoma treated with neoadjuvant chemo-immunotherapy using volumetric multisequence MRI histogram analysis. Neuroradiology. 2024. PMID: 38503986. doi:10.1007/s00234-024-03339-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。